Arthrotec and Ocrevus drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Arthrotec (diclofenac sodium; misoprostol) and Ocrevus (ocrelizumab). Common drug interactions include glomerular filtration rate decreased among females and acne among males.

The phase IV clinical study analyzes what interactions people have when they take Arthrotec and Ocrevus. It is created by eHealthMe based on reports of 23 people who take the same drugs from the FDA, and is updated regularly.

What is Arthrotec?

Arthrotec has active ingredients of diclofenac sodium; misoprostol. It is often used in arthritis. eHealthMe is studying from 11,986 Arthrotec users. Check the latest studies of Arthrotec.

What is Ocrevus?

Ocrevus has active ingredients of ocrelizumab. eHealthMe is studying from 56,583 Ocrevus users. Check the latest studies of Ocrevus.



On Aug, 06, 2026

23 people who take Arthrotec and Ocrevus together, and have interactions are studied.

Arthrotec and Ocrevus drug interactions.

What are the common drug interactions of Arthrotec and Ocrevus, by gender? *:

female:

  1. Glomerular filtration rate decreased
  2. Eye disorder
  3. Teeth brittle (other half has a defect in the teeth)
  4. Toothache (tooth pain)
  5. Atonic urinary bladder (large urinary bladders that have become dilated but are not emptying properly)
  6. Bladder mass
  7. Choking (mechanical obstruction of the flow of air from the environment into the lungs)
  8. Decubitus ulcer (a chronic ulcer of the skin caused by prolonged pressure on it)
  9. Depression
  10. Dysstasia (difficulty in standing)

male:

  1. Acne (skin problems that cause pimples)
  2. Aggression
  3. Depression
  4. Diplopia (double vision)
  5. Disability
  6. Dizziness
  7. Drug hypersensitivity
  8. Dry mouth
  9. Fatigue (feeling of tiredness)
  10. Gastrointestinal disorder (functional problems of gastrointestinal tract)

What are the common drug interactions of Arthrotec and Ocrevus, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Agitation (state of anxiety or nervous excitement)
  2. Anxiety
  3. Attention deficit hyperactivity disorder (a chronic condition including attention difficulty, hyperactivity, and impulsiveness)
  4. Back pain
  5. Blindness
  6. Constipation
  7. Cough
  8. Dehydration (dryness resulting from the removal of water)
  9. Depression
  10. Diplopia (double vision)

30-39:

n/a

40-49:

  1. Headache (pain in head)
  2. Somnolence (a state of near-sleep, a strong desire for sleep)
  3. Fatigue (feeling of tiredness)
  4. Jessner's lymphocytic infiltration (collections of lymphocytes, macrophages, and dendritic cells in the skin)
  5. Hypoaesthesia (reduced sense of touch or sensation)
  6. Infusion related reaction
  7. Alopecia (absence of hair from areas of the body)
  8. Chest discomfort
  9. Cough
  10. Cyst (a closed sac)

50-59:

n/a

60+:

  1. Blood pressure increased
  2. Cough
  3. Lymphocyte count decreased
  4. Incisional hernia (hernia caused by an incompletely-healed surgical wound)
  5. Sensory disturbance (sense disturbance)
  6. Blood creatinine increased
  7. Glomerular filtration rate decreased
  8. Atonic urinary bladder (large urinary bladders that have become dilated but are not emptying properly)
  9. Bladder mass
  10. Decubitus ulcer (a chronic ulcer of the skin caused by prolonged pressure on it)

What are the existing conditions these people have? *

  1. Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 11 people, 47.83%
  2. Secondary Progressive Multiple Sclerosis (a stage of ms which comes after relapsing remitting ms in many cases): 10 people, 43.48%
  3. Pain: 10 people, 43.48%
  4. Primary Progressive Multiple Sclerosis (primary progressive inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 9 people, 39.13%
  5. High Blood Pressure: 9 people, 39.13%
  6. Cervical Spinal Stenosis (narrowing of the spinal canal in the neck): 9 people, 39.13%
  7. Progressive Relapsing Multiple Sclerosis (chronic autoimmune disease of the central nervous system in which gradual destruction of myelin occurs in patches throughout the brain or spinal cord or both): 8 people, 34.78%
  8. Acne (skin problems that cause pimples): 8 people, 34.78%
  9. Insomnia (sleeplessness): 6 people, 26.09%
  10. Panic Disorder: 2 people, 8.70%

* Approximation only. Some reports may have incomplete information.

Do you take Arthrotec and Ocrevus?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Arthrotec and Ocrevus:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Arthrotec:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Ocrevus:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Arthrotec and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Ocrevus and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on diclofenac sodium; misoprostol and ocrelizumab (the active ingredients of Arthrotec and Ocrevus, respectively), and Arthrotec and Ocrevus (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: